Assessment of cardiovascular risk on the SCORE and SCORE2 scales among the male population

To assess cardiovascular risk, old methods are being reviewed and new, more objective and easy-to-use methods are being proposed, taking into account new epidemiological, economic and nutritional transformations. This approach allows you to expand the circle of people who need to be monitored.
Objective. To compare the level of cardiovascular risk on the SCORE and SCORE2 scales among an almost healthy male population.
Object and methods. The study was conducted among the male population aged 40-59 years. 419 people were included. The risk of cardiovascular complications was calculated for each respondent using SCORE and SCORE2. The statistical analysis was carried out in the StatTech v. program. 4.7.1.
Results. According to the SCORE scale, the respondents were distributed as follows: in the 40–44–year–old group, 10 subjects were in the low-risk group, 38 were in the moderate group; in the 45–49-year-old group, 59 were in moderate risk, 22 were in high risk, and 1 was in very high risk. In the 50–54-year-old group, 56 were at moderate risk, 40 were at high risk, and 7 were at very high risk. In the 54–59- year-old group, 36 people were in the moderate-risk group, 48 were in the high-risk group, and 34 were in the very high-risk group. On the SCORE2 scale, the same respondents were included in the high- and very high-risk groups. At the same time, the risk of complications increased by 9% (p < 0.001). The respondents with HDL-C levels of less than 3.99 mmol/L on the SCORE scale were distributed as follows: in the 40–44 year group, 3 were in the low–risk group, 6 were in the moderate risk group; in the 45–49 year group, 16 were in the moderate risk group. In the 50–54 year old group, 19 were at moderate risk. In the 54–59-year-old group, 20 people were in the moderate risk group, 4 were at high risk, and 34 were very high. According to the SCORE2 scale, the same respondents were included in the high and very high risk groups. The risk of complications increased by 10% (p < 0.001).
Conclusion. The SCORE2 scale makes it possible to assess the risk of cardiac events in a wider range of people, to monitor them more actively in the future, and to expand indications for therapy.

1. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;23(6):7-122. (in Russ). https://doi.org/10.15829/1560- 4071-2018-6-7-122

2. Boytsov S.A., Pogosova N.V., Ansheles A.A. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452. (in Russ). https://doi.org/10.15829/1560-4071-2023-5452

3. Boytsov SA, Pogosova NV, Bubnova MG, Drapkina OM, Gavrilova NE, Eganyan RA, et al. Cardiovascular prevention 2017. National guidelines. Russian journal of cardiology. 2018;(6):7-122. (in Russ.) https://doi.org/10.15829/1560-4071-2018-6-7-122.

4. Lale Tokgozoglu, ChristianTorp-Pedersen. Redefining cardiovascular risk prediction: is the crystal ball clearer now? European Heart Journal. 2021;42:2468–2471. https://doi.org/10.1093/eurheartj/ehab310

5. World Health Organization website: cardiovascular diseases. [Electronic resource]. May 17, 2017 URL: https://www.who.int/ru/newsroom/fact-sheets/detail/cardiovascular-diseases-(cvds)

6. Mortensen M.B., Tybjærg-Hansen A., Nordestgaard B.G. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines. JAMA Cardiol. 2022;7(8):836–43. https://doi.org/10.1001/jamacardio.2022.1876

7. Lagutina S.N., Pashkova A.A., Dobrynina I.S. Comparative analysis of risk assessment of fatal and nonfatal cardiovascular events using SCORE/SCORE2 in patients at the outpatient stage. Therapist's Bulletin. 2023; 4(59). (in Russ.) https://doi.org/ 10.31550/2712-8601-VT-2023-4-3.

8. Sergienko IV, Ansheles AA, Boytsov SA. Mobile application “Aterostop” for a comprehensive assessment of cardiovascular risk in patients in the Russian population. Terapevticheskii Arkhiv. 2021;4(93):415-420. (in Russ.) https://doi.org/10.26442/00403660.2021.04.20068

9. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42:2439–2454. https://doi.org/10.1093/eurheartj/ehab309

10. Erina A.M., Usoltsev D.A., Boyarinova M.A. Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). Russian Journal of Cardiology. 2022;27(5):5006. (in Russ.) https://doi.org/10.15829/1560-4071-2022-5006

11. Tregubov A.V., Tregubova A. A., Alekseeva I. V., Savchuk K. I., Urazgildeeva S. A. Experience in using the SCORE and SCORE2 scales to assess the risk of cardiovascular complications in residents of the Russian Federation. Atherosclerosis and Dyslipidemia. 2022;3(48):41–47. (in Russ.) https://doi.org/10.34687/2219-8202.JAD.2022.03.0005